CD19 and congenital rubella syndrome: Most CMV reactivations occur early on after CAR-T in the context of a dip in CMV-CMI and disproportionately affect patients with CRS/ICANS, particularly those receiving glucocorticoids, and possibly recipients of BCMA CAR-T compared to CD19 CAR-T.